Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 9
2014 9
2015 6
2016 4
2017 5
2018 6
2019 6
2020 6
2021 10
2022 17
2023 29
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Prediction of tissue-of-origin of early stage cancers using serum miRNomes.
Matsuzaki J, Kato K, Oono K, Tsuchiya N, Sudo K, Shimomura A, Tamura K, Shiino S, Kinoshita T, Daiko H, Wada T, Katai H, Ochiai H, Kanemitsu Y, Takamaru H, Abe S, Saito Y, Boku N, Kondo S, Ueno H, Okusaka T, Shimada K, Ohe Y, Asakura K, Yoshida Y, Watanabe SI, Asano N, Kawai A, Ohno M, Narita Y, Ishikawa M, Kato T, Fujimoto H, Niida S, Sakamoto H, Takizawa S, Akiba T, Okanohara D, Shiraishi K, Kohno T, Takeshita F, Nakagama H, Ota N, Ochiya T; Project Team for Development and Diagnostic Technology for Detection of miRNA in Body Fluids. Matsuzaki J, et al. Among authors: sudo k. JNCI Cancer Spectr. 2023 Jan 3;7(1):pkac080. doi: 10.1093/jncics/pkac080. JNCI Cancer Spectr. 2023. PMID: 36426871 Free PMC article.
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K. Koyama T, et al. Among authors: sudo k. Cancer Discov. 2023 Aug 4;13(8):1814-1825. doi: 10.1158/2159-8290.CD-23-0419. Cancer Discov. 2023. PMID: 37369013 Clinical Trial.
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T. Nakamura Y, et al. Among authors: sudo k. J Clin Oncol. 2023 Dec 20;41(36):5569-5578. doi: 10.1200/JCO.23.00606. Epub 2023 Sep 26. J Clin Oncol. 2023. PMID: 37751561 Free PMC article. Clinical Trial.
Molecular biomarkers in gastric cancer.
Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros A Jr, Song S, Ajani JA. Elimova E, et al. Among authors: sudo k. J Natl Compr Canc Netw. 2015 Apr;13(4):e19-29. doi: 10.6004/jnccn.2015.0064. J Natl Compr Canc Netw. 2015. PMID: 26052595 Review.
Anti-angiogenic agent ramucirumab: meaningful or marginal?
Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Wadhwa R, et al. Among authors: sudo k. Expert Rev Anticancer Ther. 2014 Apr;14(4):367-79. doi: 10.1586/14737140.2014.896207. Epub 2014 Mar 7. Expert Rev Anticancer Ther. 2014. PMID: 24605771 Review.
Evolution of gastric surgery techniques and outcomes.
Shiozaki H, Shimodaira Y, Elimova E, Wadhwa R, Sudo K, Harada K, Estrella JS, Das P, Badgwell B, Ajani JA. Shiozaki H, et al. Among authors: sudo k. Chin J Cancer. 2016 Jul 26;35(1):69. doi: 10.1186/s40880-016-0134-y. Chin J Cancer. 2016. PMID: 27460019 Free PMC article. Review.
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Ida H, Koyama T, Mizuno T, Sunami K, Kubo T, Sudo K, Tao K, Hirata M, Yonemori K, Kato K, Okusaka T, Ohe Y, Matsui Y, Yamazaki N, Ogawa C, Kawai A, Narita Y, Esaki M, Yamamoto N. Ida H, et al. Among authors: sudo k. Cancer Sci. 2022 Dec;113(12):4300-4310. doi: 10.1111/cas.15586. Epub 2022 Sep 29. Cancer Sci. 2022. PMID: 36106376 Free PMC article.
Genetic characteristics of platinum-sensitive ovarian clear cell carcinoma.
Saito R, Kuroda T, Yoshida H, Sudo K, Saito M, Tanabe H, Takano H, Yamada K, Kiyokawa T, Yonemori K, Kato T, Okamoto A, Kohno T. Saito R, et al. Among authors: sudo k. Jpn J Clin Oncol. 2023 Aug 30;53(9):781-790. doi: 10.1093/jjco/hyad045. Jpn J Clin Oncol. 2023. PMID: 37248674
Chemoradiation for esophageal cancer.
Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Blum MA, et al. Among authors: sudo k. Thorac Surg Clin. 2013 Nov;23(4):551-8. doi: 10.1016/j.thorsurg.2013.07.006. Thorac Surg Clin. 2013. PMID: 24199704 Review.
Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma.
Aiba H, Kojima Y, Shimoi T, Sudo K, Yazaki S, Imai T, Yoshida A, Iwata S, Kobayashi E, Kawai A, Arakawa A, Ogawa C, Kimura H, Yonemori K. Aiba H, et al. Among authors: sudo k. Jpn J Clin Oncol. 2023 Jun 29;53(7):604-610. doi: 10.1093/jjco/hyad031. Jpn J Clin Oncol. 2023. PMID: 37093679 Review.
112 results